



Pathogenic Microorganisms and Antibiotic Therapy in Infectious Disease

Guest Editors:

Dr. Angia Quirino

Associate Professor, Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy

Dr. Grazia Pavia

Department of Health Sciences, School of Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy

Dr. Nadia Marascio

Department of Health Sciences, Clinical Microbiology Unit, "Magna Graecia" University, Catanzaro, Italy

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editors

Dear Colleagues,

The management of patients with infections caused by multidrug-resistant (MDR) microorganisms is the greatest healthcare challenge of the 21st century. The impaired application of antibiotics and invasive diagnostic and therapeutic procedures have led to the development of resistance, mainly in Gram-positive and Gram-negative bacteria. The spread of MDR and extensively drug-resistant (XDR) strains has prompted clinicians to explore alternative therapeutic strategies against infections that offer a more targeted approach to treatment. An enhanced understanding of the pathogenic mechanisms of AMR should hopefully lead to innovative therapeutic strategies for "difficult-to-treat" infections and to the development of antimicrobial drugs that offer the greatest spectrum of activity while possessing the lowest chance of resistance.

This Special Issue welcomes the submission of manuscripts that offer insights into the surveillance, epidemiology, genomics of antimicrobial resistance genes, novel antimicrobial stewardship approaches in the critically ill patient population and stewardship strategies employing novel antimicrobial therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)